VarmX to present at the American Society of Hematology (ASH) Annual Meeting & Exposition
December 1, 2025 – Biotechnology, Clinical Trials, Other, Pharmaceutical – ASH 2025, VarmX, clinical trials, direct oral anticoagulants, hemostasis, inherited coagulation disorders, thrombosis
Poster presentation highlights Phase 1 data showing VMX-C001 has no effect on the anticoagulant function of heparin in healthy subjects
1 December 2025 — Leiden, The Netherlands — VarmX, a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and treatment of inherited coagulation disorders, will be presenting Phase 1 clinical data on lead asset, VMX-C001 in a poster presentation at the 67th ASH Annual Meeting and Exposition in Orlando, Florida from 6-9 December 2025.
VarmX’s CMO, Dr Ged Short,will present the poster VMX-C001 has no effect on the anticoagulant function of heparin in healthy subjects on 8 December at from 6pm at the Orange County Convention Center, West Halls B3-B4, as part of Session 321, Coagulation and Fibrinolysis: Basic and Translational.
The poster presentation highlights the findings from the Phase 1 single site, open-label study of VMX-C001 in healthy subjects, demonstrating that VMX-C001 with or without a FXa DOAC did not impact the anticoagulant activity of Unfractionated heparin (UFH) or Low Molecular Weight Heparin (LMWH).
Thus, VMX-C001 can restore coagulation in people taking FXa DOACs, without affecting UFH administered immediately after VMX-C001 for anticoagulation during vascular surgery or for cardiopulmonary bypass and LMWH can be used as thromboprophylaxis or anticoagulation in individuals administered VMX-C001.
The abstract for the poster presentation can be found here: https://meetings-api.hematology.org/api/abstract/vmpreview/290515.
About VarmX
VarmX is a spin-off from the Leiden University Medical Center (LUMC), founded in 2016 by Professor Pieter Reitsma, a world leading expert in hemostasis and thrombosis. VarmX’s lead compound VMX-C001 is a modified recombinant blood factor X. The compound is being developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The Company is supported by a strong syndicate of investors including Sound Bioventures, EIC, EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures and InnovationQuarter. For more information, please visit www.varmx.com.
